Hepatocellular Carcinoma Non-resectable

Oncology
5
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 3 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
ABT-869Phase 31 trial
Active Trials
NCT01009593Terminated1,035Est. Jul 2012
Ipsen
IpsenChina - Tianjin
1 program
1
CabozantinibPhase 2Small Molecule1 trial
Active Trials
NCT04511455Completed22Est. Dec 2024
Akesobio
AkesobioChina - Zhongshan
1 program
1
HAICPhase 21 trial
Active Trials
NCT06187961RecruitingEst. Jun 2027
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
ETBX-011Phase 1/21 trial
Active Trials
NCT03563170Withdrawn0Est. Aug 2019
E
EisaiChina - Liaoning
1 program
1
LenvatinibPhase 1/2Small Molecule1 trial
Active Trials
NCT05901194Active Not Recruiting25Est. Apr 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AbbottABT-869
AkesobioHAIC
IpsenCabozantinib
EisaiLenvatinib
ImmunityBioETBX-011

Clinical Trials (5)

Total enrollment: 1,082 patients across 5 trials

NCT01009593AbbottABT-869

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Start: Jan 2010Est. completion: Jul 20121,035 patients
Phase 3Terminated
NCT06187961AkesobioHAIC

Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma

Start: Dec 2023Est. completion: Jun 2027
Phase 2Recruiting
NCT04511455IpsenCabozantinib

Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Start: Dec 2020Est. completion: Dec 202422 patients
Phase 2Completed
NCT05901194EisaiLenvatinib

Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma

Start: Jul 2024Est. completion: Apr 202725 patients
Phase 1/2Active Not Recruiting
NCT03563170ImmunityBioETBX-011

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Start: May 2018Est. completion: Aug 20190
Phase 1/2Withdrawn

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,082 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)